Stephen Slade, MD
Ophthalmology · Houston, TXNPI 1386693752
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $364,284 of the $530,155 with a category attached, or 68.7%. Rxsight Inc accounts for 71.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $363,550 and has fallen 95.4% since, to $16,857 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $2163.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$381K
- Lensar, Inc.$63K
- Alcon Research LLC$29K
- Alcon$29K
- Johnson & Johnson Surgical Vision, Inc.$21K
- Novartis$3K
- plus $5K from 15 others
Across 266 payments — averaging $3180.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$605K
- Johnson & Johnson Surgical Vision, Inc.$97K
- Alcon Research LLC$56K
- Avedro Inc.$55K
- Glaukos Corporation$19K
- Bausch Health US, LLC$13K
Across 6 payments — averaging $15,181 each. An ownership or investment interest held by the physician or an immediate family member.
- Lensar, Inc.$91K
- Rxsight Inc$0
What the payments were for
- Consulting fees$152,26829%
- Speaking & faculty fees$364,28469%
- Travel & lodging$2,2310%
- Food & beverage$11,0382%
- Gifts$1570%
- Entertainment$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 32 | $381,287 |
| Lensar, Inc. | 34 | $62,856 |
| Alcon Research LLC | 21 | $29,053 |
| Alcon | 57 | $28,519 |
| Johnson & Johnson Surgical Vision, Inc. | 25 | $20,550 |
| Novartis | 13 | $2,734 |
| Beaver-visitec International, Inc. | 1 | $2,500 |
| AbbVie(2 entities) | 11 | $1,303 |
| Glaukos Corporation | 14 | $381 |
| Bausch & Lomb Americas Inc. | 10 | $219 |
| Johnson & Johnson Vision Care, Inc. | 1 | $140 |
| Sun Pharmaceutical Industries Inc. | 6 | $132 |
| Harrow Eye, LLC | 4 | $118 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $105 |
| Biotissue Holdings Inc. | 5 | $99 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $43 |
| Carl Zeiss Meditec USA, Inc. | 1 | $36 |
| Thea Pharma Inc. | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$380,168
- RXSIGHT INJECTOR HANDPIECE$380,168
- RXSIGHT INJECTOR CARTRIDGE$380,168
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$380,168
- LIGHT ADJUSTABLE LENS (LAL)$358,920
- LENSAR LASER SYSTEM$62,526
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$21,248
- Catalys Laser System$13,861
- COMPACT INTUITIV Phacofragmentation System$12,950
- Tecnis Multifocal Family of 1-piece IOLS$11,550
- LenSx$7,175
- Clareon$5,674
- Wavelight Refractive Suite$5,628
- Systane$5,425
- ILUX$5,425
- NGENUITY$4,900
- Tecnis IOL$3,926
- STAR S4 IR$3,500
- Compact Intuitiv$3,500
- XIIDRA$2,520
How this compares
$530,155 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 125 | $129,975 |
| XiidraLifitegrast | 122 | $120,098 |
| ProlensaBromfenac Sodium | 179 | $61,319 |
| LumiganBimatoprost | 36 | $20,113 |
| Bromfenac Sodium | 104 | $19,665 |
| Prednisolone Acetate | 468 | $19,194 |
| VyzultaLatanoprostene Bunod | 30 | $12,855 |
| TyrvayaVarenicline Tartrate | 17 | $11,012 |
| CequaCyclosporine | 12 | $10,833 |
| MieboPerfluorohexyloctane/Pf | 11 | $8,082 |
| Loteprednol Etabonate | 58 | $6,993 |
| Cyclosporine | 18 | $6,627 |
| IlevroNepafenac | 14 | $5,157 |
| Brimonidine Tartrate | 42 | $4,917 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $4,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,303 | $154,607180 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $219 | $141,035163 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm | $105 | $72,524254 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $21 | $11,01217 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $132 | $10,83312 claims |
| NovartisIlevro | $2,734 | $5,15714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
- Rahul PanditHouston$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.